In Silico Bioequivalence – to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
In silico SD Bioequivalence trial to replace clinical trial
The Sponsor intended to have a bio-waiver for the formulation prepared with revised PSD of API. The Sponsor had performed a BA BE study with the earlier proposed PSD of API.
Could Modeling and Simulation replace the BA BE trial by an in silico BA BE?
BA BE data of the test product and the reference were used in the analysis.
The in-silico BA BE trial was performed by means of IVIVC modeling followed by virtual BE
A validated IVIVC model (see figure) was developed and used to simulate the virtual BA BE trial.
· The Agency accepted the Sponsor’s revised API PSD limits including the in silico BA BE study.
· The Sponsor reduced costs and timelines of the new formulation development program.
In silico Quantitative Structure-Toxicity Relationship (QSTR) Model for Predicting Toxicity of Aromatic Aldehydes using Extended Topochemical Atom (ETA) Indices.
In silico SD Bioequivalence trial to replace clinical trial
In silico clinical trial to support label extension.
Connect with our in silico team of experts to discuss AI solutions and advanced modeling and simulation for the Pharma and Life Science industries and hyper accelerate your success
Our Locations
Copyrights 2024 Ikiminds Pvt Ltd. All Rights Reserved